Stock CVM CEL-SCI CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials CEL-SCI Corporation

Equities

CVM

US1508376076

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
1.16 USD -1.69% Intraday chart for CEL-SCI Corporation -10.08% -57.35%
06-20 CEL-SCI Corporation Presents Head & Neck Cancer Data At Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated with Multikine in the Target Population CI
05-15 CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 313.4 492.5 472.9 134 59.08 62.83 - -
Enterprise Value (EV) 1 313.4 492.5 472.9 134 54.93 49.73 53.79 62.83
P/E ratio -12.6 x -15.5 x -12.2 x -3.55 x -1.71 x -1.98 x -3.09 x -4.83 x
Yield - - - - - - - -
Capitalization / Revenue 677 x 881 x - - - - - 4.95 x
EV / Revenue 677 x 881 x - - - - - 4.95 x
EV / EBITDA - - - -4.16 x -2 x -1.23 x -1.75 x -
EV / FCF - - - -7.1 x -2.37 x -1.26 x -1.66 x -
FCF Yield - - - -14.1% -42.3% -79.4% -60.2% -
Price to Book - - - - 4.49 x 2.9 x 4 x -
Nbr of stocks (in thousands) 35,055 38,624 43,028 43,367 47,260 54,160 - -
Reference price 2 8.940 12.75 10.99 3.090 1.250 1.160 1.160 1.160
Announcement Date 19-12-16 20-12-29 21-12-21 22-12-27 23-12-21 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 0.4628 0.5587 - - - - - 12.7
EBITDA 1 - - - -32.23 -27.52 -40.35 -30.82 -
EBIT 1 -20.2 -28.99 -36.19 -36.06 -31.48 -36 -28.2 -16.12
Operating Margin -4,364.15% -5,188.32% - - - - - -126.92%
Earnings before Tax (EBT) 1 -22.13 -30.28 -36.36 -36.7 -32.37 -36.75 -28.95 -16.5
Net income 1 -22.13 -30.28 -36.36 -37.63 -32.37 -36.75 -28.95 -16.94
Net margin -4,783.28% -5,419.57% - - - - - -133.34%
EPS 2 -0.7100 -0.8200 -0.9000 -0.8700 -0.7300 -0.5850 -0.3750 -0.2400
Free Cash Flow 1 - - - -18.88 -23.21 -39.5 -32.38 -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 19-12-16 20-12-29 21-12-21 22-12-27 23-12-21 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - -
EBITDA - -8.573 -7.741 -7.965 -6.662 - - - - - - -
EBIT 1 - -9.552 -8.719 -8.948 -7.651 -8.176 -8.182 -7.468 - -13.56 -7.2 -7
Operating Margin - - - - - - - - - - - -
Earnings before Tax (EBT) 1 - -9.823 -9.633 -8.462 -7.854 -8.343 -8.367 -7.631 - -13.95 -7.4 -7.2
Net income 1 -8.783 -9.823 -9.927 -9.097 -8.025 -8.343 -8.367 -7.631 -6.71 -13.95 -7.4 -7.2
Net margin - - - - - - - - - - - -
EPS 2 -0.2000 -0.2300 -0.2300 -0.2100 -0.1800 -0.1900 -0.1900 -0.1600 -0.1400 -0.2800 -0.1300 -0.1100
Dividend per Share - - - - - - - - - - - -
Announcement Date 22-02-11 22-05-13 22-08-12 22-12-27 23-02-14 23-05-12 23-08-11 23-12-21 24-02-14 24-05-15 - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - - - 4.15 13.1 9.03 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - -18.9 -23.2 -39.5 -32.4 -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - - - 0.2800 0.4000 0.2900 -
Cash Flow per Share - - - - - - - -
Capex 1 - - - 0.64 0.36 3.62 3.14 -
Capex / Sales - - - - - - - -
Announcement Date 19-12-16 20-12-29 21-12-21 22-12-27 23-12-21 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.16 USD
Average target price
6.6 USD
Spread / Average Target
+468.97%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CEL-SCI CORPORATION Stock CEL-SCI Corporation
-57.35% 62.83M
CSL LIMITED Stock CSL Limited
+2.99% 95.18B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-4.34% 37.55B
BIOGEN INC. Stock Biogen Inc.
-10.41% 33.75B
UCB Stock UCB
+75.79% 28.2B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.61% 15.63B
INCYTE CORPORATION Stock Incyte Corporation
-3.46% 13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.31% 11.5B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+184.77% 10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-54.13% 9.23B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. CVM Stock
  4. Financials CEL-SCI Corporation